Rituximab or Azathioprine for EGPA Maintenance? A French study has shown that rituximab is more effective than azathioprine at maintaining remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) on chronic prednisone. https://t.co/UrHqPBVibn https://t.co/ZumTjOcrEa

"Connect with colleagues across disciplines to make a difference for your patients with PsA” – Dr. Saakshi Khattri, Rheumatologist Learn how collaborative action can help improve patient outcomes. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/rp2e5oknVF https://t.co/OOnXL6nUaI

Takayasu Arteritis: Do TNFis or IL-6- inhibitors come out on top? The treatment of active TAK is imperative to quiet vascular inflammation and subsequently maintain vascular integrity while preventing vessel damage. https://t.co/J1EQHGzR5O https://t.co/w3rQ3AbrYt

Medicaid adults w/ new low back pain Rx w/ higher-dose opioids have a 2.5 fold risk of later opioid use disorder or overdose. Retro study of ~400K opioid naive LBP pts https://t.co/9CTqaQ17vz https://t.co/hCY9KwCqLx

CLARITY-1 & CLARITY-2 Phase 3 Trials show Brepocitinib effective in Non-Infectious Uveitis. 371 pts Rx w. brepocitinib 45 mg or placebo x48wks w/ 2 wks of Pred taper. Time to Rx failure greater w/ BREP (48 vs 12 wks PBO; p<0.0001)https://t.co/EBaWe7TJbt https://t.co/UVg188eEHZ

Beverages & relative risk of hyperuricemia (HUA) & gout. Metanalysis of 52 studies shows alcohol has signif high risk of gout (OR  1.8) & HUA (OR 1.5); & sugar-sweetened beverages (SSBs) incr gout (1.37) & HUA (1.48); as well as tea for HUA among female (OR = 1.29). Coffee https://t.co/nq1fKvOlgv

High TB & LTBI burden in Latin America. Review of PANLAR registry 590 IMID pts (54% GC, 44% bDMARDs (TNFi), 29% JAKi, 27% csDMARD). Only 430 (73%) had TB screening- 59 (14%) Dx w/ LTBI. @12 mos, 99 repeat TB screening - 5 new LTBI cases Dx. Only 2 (0.34%) had active TB. (CDC https://t.co/wnPdEueb4N

Rheum Survey on SCLE> In your clinic, what is the most common cause of drug-induced subacute cutaneous lupus (SCLE). CLICK HERE>> https://t.co/LdnYIw0Qw3 https://t.co/qWUqwFpLta

Novartis announced the European Commission has approved secukinumab (Cosentyx) for use in adults w/ polymyalgia rheumatica, not responding to GCs. SEC is 1st IL-17A inhibitor approved in Europe for PMR https://t.co/ASTwbSrGr2 https://t.co/KtH0AIatdq

Two crystals in one joint? Cryptococcus risk doubled with JAK inhibitors? And early damage in Sjögren’s linked to a 12–14-fold increase in lymphoma risk? Dr. Jack Cush breaks down the findings behind the numbers in this week's RheumNow roundup: - JAK inhibitors: Cryptococcal https://t.co/4RkznhyoIt

TENS does NOT work in knee OA (KOA). Sham controlled RCT of 96 KOA pts (all Rx w/ exercise) randomized to TENS or sham show no betw group difference in KOOS score at 1 mo, nor did they achieve the minimal clinically important difference. https://t.co/1xPtNn7MM0 https://t.co/GLCfzWP39D

Systematic review of CV outcomes w/ SGLT2 inhibitors- 5 studies, 11,190 IMID pts (SSc 25%, SLE 71%) SGLT2i use assoc w/ signif lower all-cause mortality and heart failure risk (no clear MI benefit). SGLT2i have establ use in NIDDM, CHF & CKD Pts. https://t.co/U28aBsQpJ8 https://t.co/g9Ak2MCJEN

JAMA Uveitis review: Uveitis peaks at 20–50 yrs; 41–60% is anterior. ~40 linked to systemic disease (HLA-B27=axSpA). 1st exclude infection (TB, toxo, herpes). Anterior UV: topical steroids. Posterior/pan UV: DMARDs first (MTX remission 52%, MMF 71%); adalimumab if refractory https://t.co/jQQGzhAm7c

van Vollenhoven’s Treatment Advances in Lupus Professor van Vollenhoven has compiled a state-of-the-art review on lupus treatment advances – current and future. SLE management is entering an unprecedented phase. https://t.co/5oCf60XmuJ https://t.co/8TGC1Y4Cqp

Comorbidity management is subpar in Rheum. Surveys of 2213 inflamm rheum Dz pts & 140 rheumatologists. Rheums think theyre OK (71-92%) screening (HTN, OP, vaccines, CA), but pts say NOT (12=33%).Rheums agree they have no structured comorbidity screening in place (time 91%, https://t.co/mqcptziRdw